return equiti ttm
updat estim zoeti follow compani third-quart earn
releas thursday morn overal quarter number ahead estim
full-year ep guidanc increas cent midpoint top-lin guidanc
also rais million respons take ep estim
year next year discuss greater detail expect
organ growth come year hold steadi rang driven part
larger diagnost portfolio steadi flow new product companion
livestock side busi near term view top-lin assumpt
potenti conserv consid last six quarter rang
impress anoth strong perform quarter abaxi
acquisit perform well quartercontribut oper growthand
companion anim busi continu strong thank dermatolog
parasiticid offer livestock portfolio also perform well quarter grow
slightli miss year-over-year growth estim manag
team shown compani abil oper well mani type environ
includ quarter trade tariff uncertainti move forward believ
diagnost introduct newer product intern market enabl
compani continu outpac broader anim health market midsingle-digit pace
maintain outperform rate zoeti given stabil busi model
prospect on-going double-digit earn reason rel valuat
model overview increas full year ep target
slightli new midpoint manag guidanc rang increas
ep target reflect expect zoetiss invest
futur growth posit compani continu deliv above-market growth
updat model assum stronger dollar headwind roughli
top line next year organ revenu growth moder versu
averag last seven quarter
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
post-cal model adjust increas estim follow
strong quarter guidanc increas
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
innov manag commentari around time combin flea tick heartworm product
simparica trio indic await approv unit state europ market launch expect
either region dermatolog portfolio continu track well despit strong penetr
alreadi cytopoint expand indic treat allerg dermat atop dermat
livestock side newer product fostera gold appear boost compani organ growth
continu increas market share global expect livestock expand compar
off-set companion anim slow last year
companion anim apoquel cytopoint combin million revenu third quarter year-
over-year increas see exhibit total million sequenti illustr high rate
accept product dermatolog sale reach million million prior quarter
manag note simparica reach million sale quarter expect moder fourth
quarter move flea tick season howev continu expect product long-term
growth driverparticularli simparica trio reach market
exhibit quarterli apoquel cytopoint sale present
livestock livestock busi slightli under-perform expect quarter growth
compar estim clear weak spot current cattl unit state compani saw
challeng beef dairi relat competit unfavor market dynam still view
broader livestock market stabl overal view potenti diagnost livestock space
medium long term potenti add nice top-lin growth although busi invest
mode intern livestock busi exceed expect domest
decreas revenu million billion expect total organ growth
compar previous expect unit state grow organ versu previous
expect intern segment increas compar previous increas ep
estim
decreas revenu estim million billion account
slightli larger foreign currenc impact organ growth target unchang decreas
oper margin assumpt expect sg expens grow line
revenu growth result increas ep estim note
see upsid potenti target next year current pace organ revenu growth sustain
valuat stock thought
zoeti trade time updat ep estim compar five-year averag time
forward earn small-cap anim health peer time higher-growth veterinari peer time
continu impress manag steadi execut result reiter outperform rate
summari revis model found exhibit
good gross gener research amort intang total oper oper expense/ incom pre-tax tax net loss attribut non-controlling net incom excl non-recurring non-recurring item net net ep excl non-recurring per average share outstand margin analysi gross metric total revenu constant oper revenu constant incom excl non-recur excl non-recur share blair compani estimatesourc compani report william blair compani llc estim import disclosur
